Ligand validation:3UJQ

GAL: beta-D-galactopyranose

GAL is a Ligand Of Interest in 3UJQ designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3UJQ_GAL_B_301	44%	72%	0.176	0.905	0.53	0.55	-	-	1	0	100%	0.7
3UJQ_GAL_C_301	35%	69%	0.176	0.866	0.55	0.63	-	-	0	0	100%	0.7
3UJQ_GAL_D_301	29%	72%	0.183	0.841	0.54	0.54	-	-	0	0	100%	0.7
3UJQ_GAL_A_301	24%	70%	0.203	0.829	0.55	0.59	-	-	0	0	100%	0.7
3UJO_GAL_B_302	64%	73%	0.138	0.937	0.5	0.56	-	-	1	0	100%	0.704
3UL2_GAL_B_303	55%	68%	0.166	0.934	0.52	0.71	-	-	0	0	100%	0.704
4Z0N_GAL_A_405	100%	74%	0.025	0.991	0.5	0.51	-	-	0	0	100%	1
8VCS_GAL_G_301	100%	29%	0.025	0.993	0.95	1.87	-	3	2	0	100%	1
4WWH_GAL_A_401	100%	64%	0.026	0.99	0.47	0.9	-	-	0	0	100%	1
5ELB_GAL_C_202	100%	58%	0.036	0.992	0.82	0.8	-	-	0	0	100%	0.6
3OGR_GAL_A_1024	99%	47%	0.053	0.987	0.79	1.26	-	1	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.